Head-to-head evidence
Diastat vs Diazepam (Valium)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: GABA-A receptor · full Epilepsy pipeline
Diastat
Marketed by Bausch Health
NCT03953820 · Phase 1/2 · completed
The study randomized participants to treatment sequences and used Diastat as an active comparator, but it was open-label and small, with 31 randomized participants. Its primary endpoints were pharmacokinetic measures rather than clinical seizure outcomes, and the registry does not clearly report whether the primary comparison met its prespecified statistical criteria.
Diazepam (Valium)
Marketed by Roche
NCT03428360 · Phase 3 · completed
This was a single-group, open-label study with no randomization, blinding, or comparator arm; 149 participants were enrolled and 130 received study drug. Its primary safety outcomes were descriptive and had no formal between-group comparison, so the findings provide limited evidence for assessing diazepam buccal film.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Diastat's landscape · Diazepam (Valium)'s landscape